IND Number: 79,599/101,943~Primary Purpose: Other - Phase 1 Clinical Pharmacology study to determine the effect of renal impairment on the exposure of DCV, ASV, BMS-791325 (fixed dosed combination) and BMS-791325 given in multiple doses~Fixed dose combination (FDC)~Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325 (DCV 3DAA FDC)
Assess the effect of renal function on the blood levels of DCV, ASV, BMS-791325.